Prot #IGM-2323-001: A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Project: Research project

Project Details

StatusActive
Effective start/end date4/10/23 → 4/10/26

Funding

  • Covance Inc. (Prot #IGM-2323-001)
  • IGM Biosciences, Inc. (Prot #IGM-2323-001)